Body mass does not affect the remission of psoriatic arthritis patients on anti-TNF-α therapy

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Scandinavian Journal of Rheumatology

• Publication date

  2013-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3109/03009742.2012.715186PMID 22991950
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Obesity and the prediction of minimal disease activity: A prospective study in psoriatic arthritis

  2013influential reference
• Impact of body mass index on retention rates of anti-TNF-alfa drugs in daily practice for psoriasis

  2012cited by this paper
• New remission criteria for RA: ‘modern times’ in rheumatology—not a silent film, rather a 3D movie

  2011cited by this paper
• Correlation between BMI and PASI in patients affected by moderate to severe psoriasis undergoing biological therapy

  2010cited by this paper
• Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register

  2010cited by this paper
• Obesity and psoriasis: from the Medical Board of the National Psoriasis Foundation.

  2010cited by this paper
• Obesity and inflammation--targets for OA therapy.

  2010cited by this paper
• Relationship of psoriasis severity to obesity using same‐gender siblings as controls for obesity

  2009cited by this paper
• Influence of body mass index, comorbidities and prior systemic therapies on the response of psoriasis to adalimumab: an exploratory analysis from the APHRODITE data.

  2008cited by this paper
• Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors

  2006cited by this paper
• Classification criteria for psoriatic arthritis: development of new criteria from a large international study.

  2006cited by this paper
• Guideline for anti-TNF-alpha therapy in psoriatic arthritis.

  2005cited by this paper
• Guideline for anti-TNF-α therapy in psoriatic arthritis

  2005cited by this paper
• Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria.

  1996cited by this paper
• Bmc Musculoskeletal Disorders Das-28-based Eular Response and Haq Improvement in Rheumatoid Arthritis Patients Switching between Tnf Antagonists

  year unknowncited by this paper

• Factors predicting treatment response to biological and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis – a systematic review and meta-analysis

  2024cites this paper
• Interleukin-17–targeted treatment in patients with spondyloarthritis and associated cardiometabolic risk profile

  2023cites this paper
• Effect of body mass index on treatment response of biologic-/targeted synthetic-DMARDs in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis. A systematic review.

  2023cites this paper
• Effects of physical exercise and body weight on disease-specific outcomes of people with rheumatic and musculoskeletal diseases (RMDs): systematic reviews and meta-analyses informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs

  2022cites this paper
• Do genetics contribute to TNF inhibitor response prediction in Psoriatic Arthritis?

  2022cites this paper
• Minimal disease activity and remission in patients with psoriatic arthritis with elevated body mass index: an observational cohort study in the Swiss Clinical Quality Management cohort

  2022cites this paper
• Effectiveness of Systemic Therapies in Patients with Obesity and Psoriasis: A Single-center Retrospective Study.

  2021cites this paper
• The influence of obesity on biological agents treatment response in psoriatic arthritis: HUR-BIO real life results

  2021cites this paper
• Comorbidities, pain and fatigue in psoriatic arthritis, psoriasis and healthy controls: a clinical cohort study.

  2020cites this paper
• The Interrelations between Biological and Targeted Synthetic Agents Used in Inflammatory Joint Diseases, and Obesity or Body Composition

  2020cites this paper
• Is obesity a predictor for lack of response to treatment in psoriatic arthritis? A systematic review

  2020cites this paper
• Impact of Plan-Level Access Restrictions on Effectiveness of Biologics Among Patients with Rheumatoid or Psoriatic Arthritis

  2019cites this paper
• Impact of obesity on the efficacy of different biologic agents in inflammatory diseases: A systematic review and meta-analysis.

  2019cites this paper
• Influence de l’obésité sur l’efficacité de différents agents biologiques dans les maladies inflammatoires : revue systématique et méta-analyse

  2019cites this paper
• A systematic review of the association of obesity with the outcomes of inflammatory rheumatic diseases.

  2019cites this paper
• Skin changes in the obese patient.

  2019cites this paper
• [Musculoskeletal relevance of obesity: a new approach to an old topic].

  2019cites this paper
• Is Obesity a Predictor for Lack of Response to Treatment in Psoriatic Arthritis? A Systematic Review.

  2019cites this paper
• Musculoskeletal relevance of obesity : a new approach to an old topic

  2019influential citation
• Az elhízás mozgásszervi vonatkozásai: egy régi téma új megközelítésben

  2019cites this paper
• Age determines response to anti-TNFα treatment in patients with ankylosing spondylitis and is related to TNFα-producing CD8 cells

  2018cites this paper
• Using Acute-phase Reactants to Inform the Development of Instruments for the Updated Psoriatic Arthritis Core Outcome Measurement Set

  2018cites this paper
• Obesity and response to anti-tumor necrosis factor-α agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis

  2018cites this paper
• The influence of obesity on response to tumour necrosis factor-α inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries.

  2016cites this paper
• Impact of body weight on the achievement of minimal disease activity in patients with rheumatic diseases: a systematic review and meta-analysis

  2016cites this paper
• Impact of obesity on the clinical outcome of rheumatologic patients in biotherapy.

  2016cites this paper
• Is obesity in psoriatic arthritis associated with a poorer therapeutic response and more adverse effects of treatment with an anchor drug?

  2016cites this paper
• Is Obesity in Psoriatic Arthritis Associated With a Poorer Therapeutic Response and More Adverse Effects of Treatment With an Anchor Drug

  2016cites this paper
• Se asocia la obesidad en la artritis psoriásica a una menor respuesta terapéutica y más efectos adversos con el tratamiento de fondo

  2016cites this paper
• Obesity reduces the drug survival of second line biological drugs following a first TNF-α inhibitor in rheumatoid arthritis patients.

  2015cites this paper
• Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systematic review and meta-analysis

  2015cites this paper
• L’obésité diminue le maintien thérapeutique des traitements biologiques de seconde ligne après échec d’un anti-TNF de première ligne au cours de la polyarthrite rhumatoïde☆

  2015cites this paper
• Current concepts in psoriatic arthritis: pathogenesis and management.

  2014cites this paper
• Impact of obesity on the efficacy of ustekinumab in Japanese patients with psoriasis: a retrospective cohort study of 111 patients

  2014cites this paper
• Association of NLRP3 and CARD8 genetic polymorphisms with juvenile idiopathic arthritis in a Taiwanese population

  2014cites this paper
• Update on treatment of psoriatic arthritis.

  2012cites this paper